This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Management of Nonresponse and Intolerance: Switching Strategies

Maurizio Fava, MD

Published: February 28, 2000

Article Abstract

Approximately 29% to 46% of depressed patients show only partial or no response to treatmentwith antidepressants, with intolerance a frequent cause of treatment failure or discontinuation. Cliniciansfrequently switch to other antidepressants patients who have failed to tolerate or to respond toantidepressant treatment. The switching strategy involves substitution of another agent for the agentthat has either caused intolerable side effects or has failed to induce a response. Fredman and colleagueshave recently surveyed 402 psychiatrists from various parts of the country and asked themwhat steps they would take for patients who fail to respond to 8 weeks or more of an adequate dose ofa selective serotonin reuptake inhibitor (SSRI). Interestingly, switching to a non-SSRI agent was themost popular choice indicated by psychiatrists (44% of respondents), with dual-acting agents and bupropionbeing the next most commonly chosen agents. Even though there are no controlled trials ofswitching strategies in the literature to date, clinicians often choose this course of action. This articlewill review some of the currently available studies on switching strategies.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 61

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...